| ALNYLAM PHARMACEUTICALS, INC. |
Director |
Common Stock |
16.8K |
$7.56M |
$450.00 |
Aug 18, 2025 |
Direct |
| ALNYLAM PHARMACEUTICALS, INC. |
Director |
Common Stock |
4K |
$1.8M |
$451.20 |
Aug 18, 2025 |
by Trust |
| BRISTOL MYERS SQUIBB CO |
Director |
Common Stock, $0.10 par value |
12.5K |
$622K |
$49.78 |
Jun 13, 2021 |
Direct |
| BRISTOL MYERS SQUIBB CO |
Director |
Deferred Share Units |
9.34K |
$479K |
$51.31 |
Jun 30, 2021 |
Direct |
| BRISTOL MYERS SQUIBB CO |
Director |
Common Stock, $0.10 par value |
2K |
$99.6K |
$49.78 |
Jun 13, 2021 |
By Trust |
| Magenta Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
18.2K |
|
|
Jun 1, 2021 |
Direct |
| Kaleido Biosciences, Inc. |
Director |
Stock Option (Right to Buy) |
15K |
|
|
Jun 30, 2020 |
Direct |
| ALNYLAM PHARMACEUTICALS, INC. |
Director |
Stock Option (right to buy) |
0 |
|
|
Aug 18, 2025 |
Direct |
| BRISTOL MYERS SQUIBB CO |
Director |
Restricted Stock Units |
0 |
|
$50.10 |
Jun 13, 2021 |
Direct |